410 related articles for article (PubMed ID: 14638477)
1. In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.
Otani T; Tanaka M; Ito E; Kurosaka Y; Murakami Y; Onodera K; Akasaka T; Sato K
Antimicrob Agents Chemother; 2003 Dec; 47(12):3750-9. PubMed ID: 14638477
[TBL] [Abstract][Full Text] [Related]
2. Antipneumococcal activity of DK-507k, a new quinolone, compared with the activities of 10 other agents.
Browne FA; Bozdogan B; Clark C; Kelly LM; Ednie L; Kosowska K; Dewasse B; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2003 Dec; 47(12):3815-24. PubMed ID: 14638489
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone.
Hoshino K; Inoue K; Murakami Y; Kurosaka Y; Namba K; Kashimoto Y; Uoyama S; Okumura R; Higuchi S; Otani T
Antimicrob Agents Chemother; 2008 Jan; 52(1):65-76. PubMed ID: 17938194
[TBL] [Abstract][Full Text] [Related]
4. [Comparative in vitro activity of garenoxacin (BMS-284756). Sentry program, Spain (1999-2000)].
Loza E; Cantón R; Pascual A; Tubau F; Morosini MI; Almaraz F; Perea E; Martín R; Jones RN; Baquero F
Enferm Infecc Microbiol Clin; 2003 Oct; 21(8):404-9. PubMed ID: 14525705
[TBL] [Abstract][Full Text] [Related]
5. In vitro antibacterial activity and pharmacodynamics of new quinolones.
Dalhoff A; Schmitz FJ
Eur J Clin Microbiol Infect Dis; 2003 Apr; 22(4):203-21. PubMed ID: 12687416
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models.
Andes D; Craig WA
Antimicrob Agents Chemother; 2002 Jun; 46(6):1665-70. PubMed ID: 12019073
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model.
Andes D; Craig WA
Antimicrob Agents Chemother; 2003 Dec; 47(12):3935-41. PubMed ID: 14638504
[TBL] [Abstract][Full Text] [Related]
8. Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.
Bogdanovich T; Esel D; Kelly LM; Bozdogan B; Credito K; Lin G; Smith K; Ednie LM; Hoellman DB; Appelbaum PC
Antimicrob Agents Chemother; 2005 Aug; 49(8):3325-33. PubMed ID: 16048943
[TBL] [Abstract][Full Text] [Related]
9. Activity of newer fluoroquinolones against gram-positive and gram-negative bacteria isolated from ocular infections: an in vitro comparison.
Duggirala A; Joseph J; Sharma S; Nutheti R; Garg P; Das T
Indian J Ophthalmol; 2007; 55(1):15-9. PubMed ID: 17189881
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone.
Hosaka M; Yasue T; Fukuda H; Tomizawa H; Aoyama H; Hirai K
Antimicrob Agents Chemother; 1992 Oct; 36(10):2108-17. PubMed ID: 1332587
[TBL] [Abstract][Full Text] [Related]
11. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
Noviello S; Ianniello F; Leone S; Esposito S
J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
[TBL] [Abstract][Full Text] [Related]
12. [Resistance profiles to fluoroquinolones in clinical isolates of Gram positive cocci].
Hidalgo M; Reyes J; Cárdenas AM; Díaz L; Rincón S; Vanegas N; Díaz PL; Castañeda E; Arias CA
Biomedica; 2008 Jun; 28(2):284-94. PubMed ID: 18719726
[TBL] [Abstract][Full Text] [Related]
13. [Antibacterial activity of gatifloxacin against various fresh clinical isolates in 2002].
Matsuzaki K; Watabe E; Yoshimori K; Shikano M; Sato Y; Hasegawa M; Kobayashi I
Jpn J Antibiot; 2002 Dec; 55(6):800-7. PubMed ID: 12621734
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
Blondeau JM; Laskowski R; Bjarnason J; Stewart C
Int J Antimicrob Agents; 2000 Feb; 14(1):45-50. PubMed ID: 10717500
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci.
Entenza JM; Vouillamoz J; Glauser MP; Moreillon P
Antimicrob Agents Chemother; 2004 Jan; 48(1):86-92. PubMed ID: 14693523
[TBL] [Abstract][Full Text] [Related]
16. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.
Brueggemann AB; Coffman SL; Rhomberg P; Huynh H; Almer L; Nilius A; Flamm R; Doern GV
Antimicrob Agents Chemother; 2002 Mar; 46(3):680-8. PubMed ID: 11850248
[TBL] [Abstract][Full Text] [Related]
17. In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model.
Otsu Y; Yanagihara K; Fukuda Y; Miyazaki Y; Tsukamoto K; Hirakata Y; Tomono K; Kadota J; Tashiro T; Murata I; Kohno S
Antimicrob Agents Chemother; 2003 Dec; 47(12):3699-703. PubMed ID: 14638468
[TBL] [Abstract][Full Text] [Related]
18. Activities of garenoxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model.
Azoulay-Dupuis E; Bédos JP; Mohler J; Peytavin G; Isturiz R; Moine P; Rieux V; Cherbuliez C; Péchère JC; Fantin B; Köhler T
Antimicrob Agents Chemother; 2004 Mar; 48(3):765-73. PubMed ID: 14982762
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001.
Christiansen KJ; Bell JM; Turnidge JD; Jones RN
Antimicrob Agents Chemother; 2004 Jun; 48(6):2049-55. PubMed ID: 15155198
[TBL] [Abstract][Full Text] [Related]
20. A critical review of the fluoroquinolones: focus on respiratory infections.
Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ
Drugs; 2002; 62(1):13-59. PubMed ID: 11790155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
